文献速递预防保健、筛查与疫苗慢病管理

结直肠癌风险预测(CRISP)试验:风险分层筛查决策支持工具随机对照试验

The Colorectal cancer RISk Prediction (CRISP) trial: a randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening.
PubMed 文献 · Br J Gen Pract · 2023-07-27

在澳大利亚墨尔本10家全科诊所开展随机对照试验,纳入734名50-74岁就诊患者,评估CRISP计算机化风险评估与决策支持工具对风险适宜结直肠癌筛查的影响。干预组12个月时风险适宜筛查率71.5%,对照组65.0%,绝对增加6.5%(95%CI -0.28至13.2,P=0.057);在随访期间应筛查者中,干预组59.8% vs 对照组38.9%,绝对增加20.3%(95%CI 10.3至30.4,P<0.001),主要通过增加平均风险者的粪便隐血试验实现。

要点

  • CRISP工具在全科咨询中可提高应筛查者的风险适宜结直肠癌筛查率。
  • 应筛查者中干预组筛查率59.8%,对照组38.9%,绝对增加20.3%。
  • 总体人群风险适宜筛查增加6.5%,但差异未达统计学显著(P=0.057)。

核心结论

  • 在全科诊所使用CRISP风险评估与决策支持工具可增加应筛查者的风险适宜结直肠癌筛查。
  • CRISP干预可从50岁起实施,以确保人们在最佳年龄以最具成本效益的检测开始结直肠癌筛查。

研究设计与样本

  • 随机对照试验,2017年5月至2018年5月在澳大利亚墨尔本10家全科诊所开展。
  • 从连续就诊的50-74岁全科患者中招募,共734名参与者随机分组(干预组369例,对照组365例),722例(干预组362例,对照组360例)完成主要结局判定。
  • 干预组咨询包括使用CRISP工具进行结直肠癌风险评估并讨论筛查建议,对照组咨询聚焦结直肠癌生活方式危险因素。
  • 主要结局为12个月时风险适宜结直肠癌筛查。

主要发现

  • 干预组与对照组12个月风险适宜筛查率分别为71.5%和65.0%,绝对增加6.5%(95%CI -0.28至13.2;OR 1.36,95%CI 0.99至1.86,P=0.057)。
  • 在随访期间应筛查者中,干预组筛查率59.8%,对照组38.9%,绝对增加20.3%(95%CI 10.3至30.4;OR 2.31,95%CI 1.51至3.53,P<0.001)。
  • 应筛查者中筛查率的提高主要通过增加平均风险者的粪便隐血试验实现。

临床怎么用

  • 全科医生可在50-74岁患者咨询中使用CRISP工具进行结直肠癌风险评估和决策支持,以促进风险适宜筛查。
  • 对随访期间应筛查者,CRISP工具可显著提高筛查启动率,尤其通过增加平均风险者的粪便隐血试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A risk-stratified approach to colorectal cancer (CRC) screening could result in a more acceptable balance of benefits and harms, and be more cost-effective. AIM: To determine the effect of a consultation in general practice using a computerised risk assessment and decision support tool (Colorectal cancer RISk Prediction, CRISP) on risk-appropriate CRC screening. DESIGN AND SETTING: Randomised controlled trial in 10 general practices in Melbourne, Australia, from May 2017 to May 2018. METHOD: Participants were recruited from a consecutive sample of patients aged 50-74 years attending their GP. Intervention consultations included CRC risk assessment using the CRISP tool and discussion of CRC screening recommendations. Control group consultations focused on lifestyle CRC risk factors. The primary outcome was risk-appropriate CRC screening at 12 months. RESULTS: A total of 734 participants (65.1% of eligible patients) were randomised (369 intervention, 365 control); the primary outcome was determined for 722 (362 intervention, 360 control). There was a 6.5% absolute increase (95% confidence interval [CI] = -0.28 to 13.2) in risk-appropriate screening in the intervention compared with the control group (71.5% versus 65.0%; odds ratio [OR] 1.36, 95% CI = 0.99 to 1.86, P = 0.057). In those due CRC screening during follow-up, there was a 20.3% (95% CI = 10.3 to 30.4) increase (intervention 59.8% versus control 38.9%; OR 2.31, 95% CI = 1.51 to 3.53, P<0.001) principally by increasing faecal occult blood testing in those at average risk. CONCLUSION: A risk assessment and decision support tool increases risk-appropriate CRC screening in those due screening. The CRISP intervention could commence in people in their fifth decade to ensure people start CRC screening at the optimal age with the most cost-effective test.

来源:Br J Gen Pract,查看原文。版权归原作者所有。

引用

  1. Emery JD, Jenkins MA, Saya S, et al. The Colorectal cancer RISk Prediction (CRISP) trial: a randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening. Br J Gen Pract. 2023. PMID: 37012077. doi:10.3399/BJGP.2022.0480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。